Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Sep 6;29(9):764-767.
doi: 10.1093/oncolo/oyae106.

Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report

Glaucia Alves de Souza  1 , Debora Maciel Santana Dornellas  1 , Paulo Vidal Campregher  1 , Carlos Henrique Andrade Teixeira  2 , Gustavo Schvartsman  1
Affiliations
Case Reports

Complete response to capmatinib in a patient with metastatic lung adenocarcinoma harboring CD47-MET fusion: a case report

Glaucia Alves de Souza et al. Oncologist. .

Abstract

Comprehensive genomic profiling is highly recommended for treatment decision in nonsquamous, non-small cell lung cancer (NSCLC). However, rare genomic alterations are still being unveiled, with scarce data to guide therapy. Herein, we describe the treatment journey of a 56-year-old, never-smoker Caucasian woman with a metastatic NSCLC harboring a CD47-MET fusion, initially classified as a variant of unknown significance. She had undergone 3 lines of therapy over the course of 3 years, including chemotherapy, immunotherapy, and anti-angiogenic therapy. After reanalysis of her next-generation sequencing data in our service, the fusion was reclassified as likely oncogenic. The patient was started with fourth-line capmatinib, with a good tolerance so far and a complete metabolic response in the active sites of disease, currently ongoing for 18 months. In conclusion, we highlight the sensitivity of a novel MET fusion to capmatinib and emphasize the need for comprehensive panels in NSCLC and molecular tumor board discussions with specialized centers when rare findings arise.

Keywords: MET receptor tyrosine kinase; capmatinib; case report; next-generation sequencing; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no financial conflict of interest with this manuscript.

Figures

Figure 1.
Figure 1.
Schematic representation of CD47::MET gene fusion (Arriba output).
Figure 2.
Figure 2.
Tumor response to capmatinib treatment. A: Baseline before treatment; B: 6 months after capmatinib.
See this image and copyright information in PMC

Comment in

  • Oncofusions - shaping cancer care.
    Dashi G, Varjosalo M. Dashi G, et al. Oncologist. 2025 Jan 17;30(1):oyae126. doi: 10.1093/oncolo/oyae126. Oncologist. 2025. PMID: 38833619 Free PMC article.

References

    1. Copia Sperandio R, Luiza Teixeira Tostes F, Campregher PV, et al.. EGFR-RAD51 fusion in lung adenocarcinoma with systemic and intracranial response to osimertinib: a case report and review of the literature. Lung Cancer. 2022;166:94-97. - PubMed
    1. Remon J, Hendriks L, Mountzios G, et al.. MET alterations in NSCLC—current perspectives and future challenges. J Thorac Oncol. 2023;18(4):419-435. - PubMed
    1. Pan Y, Zhang Y, Ye T, et al.. Detection of novel NRG1, EGFR, and MET fusions in lung adenocarcinomas in the Chinese population. J Thorac Oncol. 2019;14(11):2003-2008. 10.1016/j.jtho.2019.07.022 - DOI - PubMed
    1. Uhrig S, Ellermann J, Walther T, et al.. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31(3):448-460. 10.1101/gr.257246.119 - DOI - PMC - PubMed
    1. Liu J, Shen L, Qian Y, et al.. Durable response to crizotinib in an advanced lung adenocarcinoma patient harboring rare CD47-MET fusion: a case report. Transl Cancer Res. 2022;11(8):2931-2935. 10.21037/tcr-22-141 - DOI - PMC - PubMed

Publication types